Polymyositis Market Report 2026

The polymyositis market size has grown strongly in recent years. It will grow from $1.74 billion in 2025 to $1.85 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to improved understanding of autoimmune myopathies, availability of muscle biopsy diagnostics, increased use of corticosteroids, expansion of hospital diagnostic capabilities, rising identification of rare muscle disorders.

The polymyositis market size is expected to see strong growth in the next few years. It will grow to $2.34 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to growing development of targeted immune therapies, increasing integration of precision diagnostics, rising use of biologics and immunoglobulins, expansion of personalized treatment strategies, growing research into autoimmune disease mechanisms. Major trends in the forecast period include increasing use of immunosuppressive therapies, rising adoption of monoclonal antibody treatments, growing focus on accurate differential diagnosis, expansion of advanced diagnostic imaging, enhanced patient monitoring protocols.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the polymyositis market going forward. Autoimmune diseases are conditions in which the immune system mistakenly attacks healthy cells, tissues, or organs, resulting in inflammation and tissue damage. The rising incidence of autoimmune disorders is linked to genetic susceptibility that can cause an overactive immune response, combined with environmental triggers such as infections, stress, and lifestyle factors. Polymyositis illustrates how immune system dysfunction leads to muscle inflammation, offering insight into disease mechanisms and supporting the development of improved treatment approaches for related autoimmune conditions. For instance, in February 2024, according to Arthritis Australia, an Australia-based not-for-profit organization, approximately 562,378 Australians are expected to be living with rheumatoid arthritis by 2025, representing 14% of the total arthritis population. Therefore, the increasing prevalence of autoimmune diseases is driving the growth of the polymyositis market.

The growing demand for oral drugs is expected to further propel the growth of the polymyositis market going forward. Oral drugs are medications administered by mouth in the form of tablets, capsules, or liquids and absorbed through the digestive system. Demand for oral therapies is increasing due to their convenience, ease of use, and higher patient compliance compared with injectable or invasive treatments. Polymyositis is commonly managed with oral medications that reduce muscle inflammation, regulate immune activity, and improve muscle strength, helping to relieve symptoms and slow disease progression. For instance, in October 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, among 393,390 non-hospitalized adults aged 65 years and older in the United States, 45.9% received oral antiviral treatment within 30 days of diagnosis, highlighting the growing preference for oral therapies. Therefore, the rising demand for oral drugs is contributing to the growth of the polymyositis market.

Major companies operating in the polymyositis market are focusing on developing advanced treatment approaches such as stem cell therapy to improve therapeutic outcomes and slow disease progression. Stem cell therapy uses umbilical cord-derived stem cells with immunomodulatory and anti-inflammatory properties, making them a promising option for treating autoimmune conditions such as polymyositis. For instance, in December 2024, RESTEM, a US-based clinical-stage biotechnology company, received orphan drug designation from the US Food and Drug Administration for its stem cell program using umbilical cord outer lining stem cells. This program targets polymyositis and dermatomyositis by regulating immune responses and reducing muscle inflammation. Early clinical studies have shown encouraging safety and efficacy results, with potential to reduce long-term dependence on corticosteroids.

Major companies operating in the polymyositis market are Pfizer Inc., F Hoffmann La Roche AG, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Merck & Co. Inc., C H Boehringer Sohn AG & Co. KG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Fresenius SE & Co. KGaA, UCB S.A., Teva Pharmaceuticals USA Inc., Kezar Life Sciences Inc., Argenx SE, Mallinckrodt Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, Sanofi S.A., AbbVie Inc., Eli Lilly and Company, Janssen Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., CSL Behring.

North America was the largest region in the polymyositis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polymyositis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the polymyositis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the polymyositis market by increasing costs of imported biologics, diagnostic reagents, monoclonal antibodies, and immunoglobulin products. Healthcare systems in North America and Europe are most affected due to reliance on cross-border pharmaceutical sourcing, while Asia-Pacific faces cost volatility in biologic exports. These tariffs are raising treatment expenses and limiting access to advanced therapies in some regions. At the same time, they are supporting domestic biologics manufacturing, local diagnostic kit production, and regional research investments in autoimmune disease treatments.

The polymyositis market research report is one of a series of new reports that provides polymyositis market statistics, including polymyositis industry global market size, regional shares, competitors with a polymyositis market share, detailed polymyositis market segments, market trends and opportunities, and any further data you may need to thrive in the polymyositis industry. This polymyositis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Polymyositis is a chronic inflammatory muscle disorder marked by progressive muscle weakness that mainly affects skeletal muscles. It is caused by an autoimmune response in which the body’s immune system mistakenly attacks muscle fibers, leading to inflammation, muscle degeneration, and reduced strength.

The primary types of polymyositis include idiopathic polymyositis, dermatomyositis, inclusion body myositis, and overlap myositis syndromes. Idiopathic polymyositis is a rare muscle condition characterized by muscle inflammation and weakness and is commonly treated with corticosteroids. Diagnosis involves methods such as physical examination, muscle biopsy, electromyography, blood tests, and magnetic resonance imaging. Treatment options include immunosuppressants, immunoglobulins, corticosteroids, alkylating agents, monoclonal antibodies, and other medications. These therapies are distributed through channels such as offline and online pharmacies and are used by end users including hospital pharmacies, retail pharmacies, and online pharmacies.

The polymyositis market consists of revenues earned by entities by providing services such as diagnosis and testing services, pharmacological treatment services, physical therapy and rehabilitation services, and occupational therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The polymyositis market also includes sales of anti-inflammatory and pain management medications, biologic therapies, intravenous immunoglobulin (IVIG) therapy, and plasmapheresis (plasma exchange) products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.